Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07272889 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) | PHASE1 | COMPLETED | 24 | — | — | Dec 4, 2025 | Feb 17, 2026 | Apr 13, 2026 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| EE/LNG | EXPERIMENTAL | - |
| BEM/RZR | EXPERIMENTAL | - |
| BEM/RZR + EE/LNG | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ethinyl Estradioll/Levonorgestrel (EE/LNG) | DRUG | Treatment-A (EE/LNG): A single 0.03 mg/ 0.15 mg dose of EE/LNG (1 × 0.03 mg/ 0.15 mg tablet) will be administered in the morning under fasting conditions on Day 1. |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) | DRUG | Treatment-B (BEM/RZR): A 550 mg/180 mg dose of BEM/RZR (2 × 275 mg/90 mg BEM/RZR FDC tablets) will be administered once daily (QD) under fasting conditions on Days 8 to 14. |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) | DRUG | Treatment-C (BEM/RZR + EE/LNG): BEM (550 mg)/ RZR (180 mg) as 2 × 275 mg/90 mg BEM/RZR FDC tablets will be administered QD in the morning under fasting conditions on Days 15 to 19. A single 0.03 mg/0.15 mg dose of EE/LNG (1 × 0.03 mg/ 0.15 mg tablet) will be concomitantly administered with BEM/RZR on the morning of Day 15. |
Inclusion Criteria: * Healthy post-menopausal or hormonally sterile female * Minimum body weight of 50 kg and body mass index (BMI) of 18.0-30 kg/m2. * Willing to comply with the study requirements and to provide written informed consent. Exclusion Criteria: * Infected with hepatitis B virus, hep...